New peptide drugs could take aim at a broader range of proteins that cause certain cancers, viral infections, and brain ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

A phase 3 trial suggests reducing the use of cisplatin when treating nasopharyngeal carcinoma with toripalimab-based ...

The brain’s map of the body remains largely unaffected by amputation, potentially informing phantom limb pain management and ...

Advances in neovascular macular degeneration, presented at ASRS 2025, include efficacy of aflibercept 8 mg as well as ...

A UK study shows that ADHD in young women increased during the COVID-19 pandemic, peaking in the age group 20-24 years; ...

A deep-learning analysis of three-dimensional optical coherence tomography scans shows promising accuracy in distinguishing ...

About 23% of MRI scans of the hand or wrist may reveal an incidental finding, and only about 3% overall may need further ...

In nine studies (76 patients), the anti-IgE monoclonal antibody omalizumab (Xolair), given every 2-4 weeks at doses ranging ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

Children with IBD and concomitant primary sclerosing cholangitis have substantially worse outcomes, with elevated risks for ...

Early initiation of recombinant growth hormone therapy, particularly before the age of 4 years, can benefit prepubertal ...